[1. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65–72. doi: 10.1038/nrc152910.1038/nrc152915630416]Open DOISearch in Google Scholar
[2. World Health Organization (WHO). Cancer, Fact sheet February 2017 [displayed 9 September 2019]. Available at https://www.who.int/news-room/fact-sheets/detail/cancer]Search in Google Scholar
[3. Kumar S, Ahmad MK, Waseem M, Pandey AK. Drug targets for cancer treatment: an overview. Med Chem 2015;5:115–23. doi: 10.4172/2161-0444.100025210.4172/2161-0444.1000252]Open DOISearch in Google Scholar
[4. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U, Fojo AT. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl AcadSci U S A 2015;112:1571–6. doi: 10.1073/pnas.141641811210.1073/pnas.1416418112432124525605897]Open DOISearch in Google Scholar
[5. Giavazzi R, Bonezzi K, Taraboletti G. Microtubule targeting agents and the tumor vasculature. In: Fojo AT, editor. The role of microtubules in cell biology, neurobiology, and oncology. Totowa (NJ). Humana Press; 2008. p. 519–30.10.1007/978-1-59745-336-3_19]Search in Google Scholar
[6. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65. doi: 10.1038/nrc13171505728510.1038/nrc131715057285]Search in Google Scholar
[7. Dong M, Liu F, Zhou H, Zhai S, Yan B. Novel natural product and privileged scaffold-based tubulin inhibitors targeting the colchicine binding site. Molecules 2016;21:1375. doi: 10.3390/molecules2110137510.3390/2110137527754459]Open DOISearch in Google Scholar
[8. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282–93. doi: 10.1172/JCI1196429276747]Search in Google Scholar
[9. Forli S. Epothilones: from discovery to clinical trials. Curr Top Med Chem 2014;14:2312–21. doi: 10.2174/156802661466614113009585510.2174/1568026614666141130095855462978825434353]Open DOISearch in Google Scholar
[10. Crimmins MT. Synthetic approaches to the microtubule stabilizing agent (-)-laulimalide. Curr Opin Drug Discov Devel 2002;5:944–59. PMID: 12478725]Search in Google Scholar
[11. Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol 2018;28:776–92. doi: 10.1016/j.tcb.2018.05.00110.1016/j.tcb.2018.05.00129871823]Open DOISearch in Google Scholar
[12. Sapra S, Bhalla Y, Sharma S, Singh G, Nepali K, Budhiraja A, Dhar KL. Colchicine and its various physicochemical and biological aspects. Med Chem Res 2013;22:531–47. doi: 10.1007/s00044-012-0077-z10.1007/s00044-012-0077-z]Open DOISearch in Google Scholar
[13. Jain S, Vahdat LT. Eribulinmesylate. Clin Cancer Res 2011;17:6615–22. doi: 10.1158/1078-0432.CCR-11-180710.1158/1078-0432.CCR-11-180721859830]Open DOISearch in Google Scholar
[14. Modrianský M, Dvorák Z. Microtubule disruptors and their interaction with biotransformation enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:213–5. doi: 10.5507/bp.2005.02810.5507/bp.2005.028]Open DOISearch in Google Scholar
[15. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790–803. doi: 10.1038/nrd325310.1038/nrd3253]Open DOISearch in Google Scholar
[16. Prota AE, Bargsten K, Zurwerra D, Field JJ, Díaz JF, Altmann KH, Steinmetz MO. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 2013;339:587–90. doi: 10.1126/science.123058210.1126/.1230582]Open DOISearch in Google Scholar
[17. Pryor DE, O’Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109–15. doi: 10.1021/bi020211b10.1021/bi020211b]Open DOISearch in Google Scholar
[18. Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, Miller JH, Díaz JF, Steinmetz MO. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl 2014;53:1621–5. doi: 10.1002/anie.20130774910.1002/anie.201307749]Open DOISearch in Google Scholar
[19. Pellegrini F. Review: Tubulin function, action of antitubulin drugs and new drug development. Cancer Invest 2005;23:264–73. doi: 10.1081/CNV-20005597010.1081/CNV-200055970]Open DOISearch in Google Scholar
[20. Ley CD, Horsman MR, Kristjansen PE. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007;9:108–12. doi: 10.1593/neo.0673310.1593/neo.06733]Open DOISearch in Google Scholar
[21. Gutiérrez ST, Díaz-Oltra S, Falomir E, Murga J, Cardaa M, Marco JA. Synthesis of combretastatin A-4 O-alkyl derivatives and evaluation of their cytotoxic, antiangiogenic and antitelomerase activity. Bioorg Med Chem 2013;21:7267–74. doi: 10.1016/j.bmc.2013.09.06410.1016/j.bmc.2013.09.064]Open DOISearch in Google Scholar
[22. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T. Syntheses and antitumor activity of cis-restricted combretastatins, 5-membered heterocyclic analogues. Bioorg Med Chem Lett 1998;8:3153–8. doi: 10.1016/s0960-894x(98)00579-410.1016/S0960-894X(98)00579-4]Search in Google Scholar
[23. Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, Ying X, Zhou S, Wang J, Zhang X, Zhang Q. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumorneovasculature. Nanomedicine 2012;8:81–92. doi: 10.1016/j.nano.2011.05.00310.1016/j.nano.2011.05.00321664295]Search in Google Scholar
[24. Gao M, Zhang D, Jin Q, Jiang C, Wang C, Li J, Peng F, Huang D, Zhang J, Song S. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Oncotarget 2016;7:58133–41. doi: 10.18632/oncotarget.1124910.18632/oncotarget.11249529541827531898]Search in Google Scholar
[25. Abma E, Daminet S, Smets P, Ni Y, de Rooster H. Combretastatin A4-phosphate and its potential in veterinary oncology, a review. Vet Comp Oncol 2017;15:184–93. doi: 10.1111/vco.1215010.1111/vco.1215025988493]Open DOISearch in Google Scholar
[26. Marzo-Mas A, Barbier P, Breuzard G, Allegro D, Falomir E, Murga J, Carda M, Peyrot V, Marco JA. Interactions of long-chain homologues of colchicine with tubulin. Eur J Med Chem 2017;126:526–35. doi: 10.1016/j.ejmech.2016.11.04910.1016/j.ejmech.2016.11.04927915168]Open DOISearch in Google Scholar
[27. Ahmed RI, Osman EE, Awadallah FM, El-Moghazy SM. Design, synthesis and molecular docking of novel diarylcyclohexenone and diarylindazole derivatives as tubulin polymerization inhibitors. J Enzyme Inhib Med Chem 2017;32:176–88. doi: 10.1080/14756366.2016.124453210.1080/14756366.2016.1244532600992527771966]Open DOISearch in Google Scholar
[28. De Martino G, La Regina G, Coluccia A, Edler MC, Barbera MC, Brancale A, Wilcox E, Hamel E, Artico M, Silvestri R. Arylthioindoles, potent inhibitors of tubulin polymerization. J Med Chem 2004;47:6120–3. doi: 10.1021/jm049360d10.1021/jm049360d15566282]Open DOISearch in Google Scholar
[29. Tantak MP, Wang J, Singh RP, Kumar A, Shah K, Kumar D. 2-(3’-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and evaluation of antibacterial and anticancer activities. Bioorg Med Chem Lett 2015;25:4225–31. doi: 10.1016/j.bmcl.2015.07.10510.1016/j.bmcl.2015.07.105456747626298501]Open DOISearch in Google Scholar
[30. Kamath PR, Sunil D, Ajees AA, Pai KS, Das S. Some new indole-coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies. Bioorg Chem 2015;63:101–9. doi: 10.1016/j.bioorg.2015.10.00110.1016/j.bioorg.2015.10.00126469742]Open DOISearch in Google Scholar
[31. Das Mukherjee D, Kumar NM, Tantak MP, Das A, Ganguli A, Datta S, Kumar D, Chakrabarti G. Development of novel bis(indolyl)-hydrazide-hydrazone derivatives as potent microtubule-targeting cytotoxic agents against A549 lung cancer cells. Biochemistry 2016;55:3020–35. doi: 10.1021/acs.biochem.5b0112710.1021/acs.biochem.5b0112727110637]Open DOISearch in Google Scholar
[32. Liu Y-M, Chen H-L, Lee H-Y, Liou J-P. Tubulin inhibitors: a patent review. Expert OpinTher Pat 2014;24:69–88. doi: 10.1517/13543776.2014.85924710.1517/13543776.2014.85924724313741]Open DOISearch in Google Scholar
[33. Ramya PVS, Guntuku L, Angapelly S, Digwal CS, Lakshmi UJ, Sigalapalli DK, Babu BN, Naidu VGM, Kamal A. Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors. Eur J Med Chem 2017;127:100–14. doi: 10.1016/j.ejmech.2016.12.04310.1016/j.ejmech.2016.12.04328038323]Open DOISearch in Google Scholar
[34. Zhang YL, Qin YJ, Tang DJ, Yang MR, Li BY, Wang YT, Cai HY, Wang BZ, Zhu HL. Synthesis and biological evaluation of 1-methyl-1H-indole-pyrazoline hybrids as potential tubulin polymerization inhibitors. Chem Med Chem 2016;11:1446–58. doi: 10.1002/cmdc.20160013710.1002/cmdc.20160013727159418]Open DOISearch in Google Scholar
[35. Wang YT, Cai XC, Shi TQ, Zhang YL, Wang ZC, Liu CH, Zhu HL. Synthesis, molecular docking and biological evaluation of 1-phenylsulphonyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as novel potential tubulin assembling inhibitors. Chem Biol Drug Des 2017;90:112–8. doi: 10.1111/cbdd.1293210.1111/cbdd.1293228032450]Search in Google Scholar
[36. Guggilapu SD, Lalita G, Reddy TS, Prajapti SK, Nagarsenkar A, Ramu S, Brahma UR, Lakshmi UJ, Vegi GMN, Bhargava SK, Babu BN. Synthesis of C5-tethered indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors. Eur J Med Chem 2017;28:1–12. doi: 10.1016/j.ejmech.2017.01.02610.1016/j.ejmech.2017.01.02628131777]Open DOISearch in Google Scholar
[37. Chennamaneni S, Gan C, Lama R, Zhong B, Su B. Indomethacin derivatives as tubulin stabilizers to inhibit cancer cell proliferation. Bioorg Med Chem 2016;24:277–85. doi: 10.1016/j.bmc.2015.12.01610.1016/j.bmc.2015.12.01626712098]Open DOISearch in Google Scholar
[38. Baytas SN, Inceler N, Yilmaz A, Olgac A, Menevse S, Banoglu E, Hamel E, Bortolozzi R, Viola G. Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors. Bioorg Med Chem 2014;22:3096–104. doi: 10.1016/j.bmc.2014.04.02710.1016/j.bmc.2014.04.027409168024816066]Open DOISearch in Google Scholar
[39. Ghinet A, Moise IM, Rigo B, Homerin G, Farce A, Dubois J, Bîcu E. Studies on phenothiazines, new microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents. Bioorg Med Chem 2016;24:2307–17. doi: 10.1016/j.bmc.2016.04.00110.1016/j.bmc.2016.04.00127073050]Open DOISearch in Google Scholar
[40. Ali I, Lone MN, Al-Othman ZA, Al-Warthan A, Sanagi MM. Heterocyclic scaffolds: centrality in anticancer drug development. Curr Drug Targets 2015;16:711–34. doi: 10.2174/138945011666615030911592210.2174/138945011666615030911592225751009]Open DOISearch in Google Scholar
[41. Singh S, Ahmad A, Raghuvanshi DS, Hasanain M, Agarwal K, Dubey V, Fatima K, Alam S, Sarkar J, Luqman S, Khan F, Tandon S, Gupta A. Synthesis of 3,5-dihydroxy-7,8-dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one derivatives as anticancer agents. Bioorg Med Chem Lett 2016;26:5322–7. doi: 10.1016/j.bmcl.2016.09.03610.1016/j.bmcl.2016.09.03627671497]Open DOISearch in Google Scholar
[42. Andújar I, Ríos JL, Giner RM, Recio MC. Pharmacological properties of shikonin - a review of literature since 2002. Planta Med 2013;79:1685–97. doi: 10.1055/s-0033-135093410.1055/s-0033-135093424155261]Open DOISearch in Google Scholar
[43. Andújar I, Ríos JL, Giner RM, Recio MC. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells. Eur J Pharm Sci 2013;49:637–41. doi: 10.1016/j.ejps.2013.05.01810.1016/j.ejps.2013.05.01823727294]Open DOISearch in Google Scholar
[44. Huang CS, Lin AH, Yang TC, Liu KL, Chen HW, Lii CK. Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFκB activation via up-regulation of PI3K/Akt/Nrf2-dependent antioxidation in EA.hy926 endothelial cells. Biochem Pharmacol 2015;93:352–61. doi: 10.1016/j.bcp.2014.12.00510.1016/j.bcp.2014.12.00525541286]Open DOISearch in Google Scholar
[45. Skrzypczak A, Przystupa N, Zgadzaj A, Parzonko A, Sykłowska-Baranek K, Paradowska K, Nałęcz-Jawecki G. Antigenotoxic, anti-photogenotoxic and antioxidant activities of natural naphthoquinone shikonin and acetylshikonin and Arnebiaeuchroma callus extracts evaluated by the umu-test and EPR method. Toxicol In Vitro 2015;30:364–72. doi: 10.1016/j.tiv.2015.09.02910.1016/j.tiv.2015.09.02926434532]Open DOISearch in Google Scholar
[46. Liang D, Sun Y, Shen Y, Li F, Song X, Zhou E, Zhao F, Liu Z, Fu Y, Guo M, Zhang N, Yang Z, Cao Y. Shikonin exerts anti-inflammatory effects in a murine model of lipopolysaccharide-induced acute lung injury by inhibiting the nuclear factor-kappa B signaling pathway. IntImmunopharmacol 2013;16:475–80. doi: 10.1016/j.intimp.201310.1016/j.intimp.2013]Open DOISearch in Google Scholar
[47. Liu J, Wang P, Xue YX, Li Z, Qu CB, Liu YH. Enhanced antitumor effect of shikonin by inhibiting Endoplasmic Reticulum Stress via JNK/c-Jun pathway in human glioblastoma stem cells. Biochem Biophys Res Commun 2015;466:103–10. doi: 10.1016/j.bbrc.2015.08.11510.1016/j.bbrc.2015.08.11526321663]Search in Google Scholar
[48. Qiu HY, Wang F, Wang X, Sun WX, Qi JL, Pang YJ, Yang RW, Lu GH, Wang XM, Yang YH. Design, synthesis, and biological evaluation of chalcone-containing shikonin derivatives as inhibitors of tubulin polymerization. Chem Med Chem 2017;12:399–406. doi: 10.1002/cmdc.20170000110.1002/cmdc.20170000128211616]Open DOISearch in Google Scholar
[49. Kamal A, Srikanth YV, Naseer Ahmed Khan M, Ashraf M, Kashi Reddy M, Sultana F, Kaur T, Chashoo G, Suri N, Sehar I, Wani ZA, Saxena A, Sharma PR, Bhushan S, Mondhe DM, Saxena AK. 2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers. Bioorg Med Chem 2011;19:7136–50. doi: 10.1016/j.bmc.2011.09.06010.1016/j.bmc.2011.09.06022047801]Open DOISearch in Google Scholar
[50. Kamal A, Hussaini SM, Nayak VL, Malik MS, Sucharitha ML, Shaik TB, Ashraf M, Bagul C. Synthesis of 2-anilinopyridine dimers as microtubule targeting and apoptosis inducing agents. Bioorg Med Chem 2014;22:6755–67. doi: 10.1016/j.bmc.2014.11.00110.1016/j.bmc.2014.11.00125468039]Open DOISearch in Google Scholar
[51. Kamal A, Khan MN, Srinivasa Reddy K, Rohini K. Synthesis of a new class of 2-anilino substituted nicotinylarylsulfonylhydrazides as potential anticancer and antibacterial agents. Bioorg Med Chem 2007;15:1004–13. doi: 10.1016/j.bmc.2006.10.02710.1016/j.bmc.2006.10.02717097292]Open DOISearch in Google Scholar
[52. Dorléans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, Knossow M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci USA 2009;106:13775–9. doi: 10.1073/pnas.090422310610.1073/pnas.0904223106272897019666559]Open DOISearch in Google Scholar
[53. Elmeligie S, Khalil NA, Ahmed EM, Emam SH. New 3-substituted-2-(4-hydroxyanilino) pyridine derivatives, synthesis, antitumor activity and tubulin polymerization inhibition. Arch Pharm (Weinheim) 2017;350(2):e1600256. doi: 10.1002/ardp.20160025610.1002/ardp.20160025628150327]Search in Google Scholar
[54. Liu YN, Wang JJ, Ji YT, Zhao GD, Tang LQ, Zhang CM, Guo XL, Liu ZP. Design, synthesis and biological evaluation of 1 methyl-1,4-dihydroindeno[1,2-c]pyrazole analogues as potential anticancer agents targeting tubulin colchicine binding site. J Med Chem 2016;59:5341–55. doi: 10.1021/acs.jmedchem.6b0007110.1021/acs.jmedchem.6b0007127172319]Open DOISearch in Google Scholar
[55. Ali I, Haque A, Saleem K, Hsieh MF. Curcumin-I Knoevenagel’s condensates and their Schiff’s bases as anticancer agents: synthesis, pharmacological and simulation studies. Bioorg Med Chem 2013;21:3808–20. doi: 10.1016/j.bmc.2013.04.01810.1016/j.bmc.2013.04.01823643901]Open DOISearch in Google Scholar
[56. Saleem K1, Wani WA, Haque A, Lone MN, Hsieh MF, Jairajpuri MA, Ali I. Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand. Future Med Chem 2013;5:135–46. doi: 10.4155/fmc.12.20110.4155/fmc.12.20123360139]Open DOISearch in Google Scholar
[57. Magalhaes LG, Marques FB, da Fonseca MB, Rogério KR, Graebin CS, Andricopulo AD. Discovery of a series of acridinones as mechanism-based tubulin assembly inhibitors with anticancer activity. Plos One 2016;11(8):e0160842. doi: 10.1371/journal.pone.016084210.1371/journal.pone.0160842498002827508497]Search in Google Scholar
[58. Devambatla RK, Namjoshi OA, Choudhary S, Hamel E, Shaffer CV, Rohena CC, Mooberry SL, Gangjee A. Design, synthesis, and preclinical evaluation of 4 substituted-5-methyl-furo[2,3-d]pyrimidines as microtubule targeting agents that are effective against multidrug resistant cancer cells. J Med Chem 2016;59:5752–65. doi: 10.1021/acs.jmedchem.6b0023710.1021/acs.jmedchem.6b00237559010127213719]Open DOISearch in Google Scholar
[59. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413–50. doi: 10.1023/A:102551310633010.1023/A:1025513106330]Search in Google Scholar
[60. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65–71. doi: 10.2174/156801105335256910.2174/156801105335256915720262]Open DOISearch in Google Scholar
[61. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665–7. doi: 10.1016/j.ab.2006.10.01410.1016/j.ab.2006.10.014186841017097592]Open DOISearch in Google Scholar
[62. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Díaz JF. Microtubule interactions with chemically diverse stabilizing agents, thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol 2005;12:1269–79. doi: 10.1016/j.chembiol.2005.09.0101635684410.1016/j.chembiol.2005.09.01016356844]Search in Google Scholar
[63. Kingston DGI, Jagtap PG, Yuan H, Samala L. The chemistry of taxol and related taxoids. In: Herz W, Falk H, Kirby GW, editors. Progress in the chemistry of organic natural products. Vol. 84. Wien: Springer; 2002. p. 53–225.10.1007/978-3-7091-6160-9_212132389]Search in Google Scholar
[64. Wang Y, Wang J, Wang H, Ye W. Novel taxane derivatives from Taxus wallichiana with high anticancer potency on tumor cells. Chem Biol Drug Des 2016;88:556–61. doi: 10.1111/cbdd.1278210.1111/cbdd.127822715381327153813]Open DOISearch in Google Scholar
[65. Barbier P, Tsvetkov PO, Breuzard G, Devred F. Deciphering the molecular mechanisms of anti-tubulin plant derived drugs. Phytochem Rev 2014;13:157–69. doi: 10.1007/s11101-013-9302-810.1007/s11101-013-9302-8]Open DOISearch in Google Scholar
[66. Verma K, Kannan K, Shanthi V, Sethumadhavan R, Karthick V, Ramanathan K. Exploring β-tubulin inhibitors from plant origin using computational approach. Phytochem Anal 2017;28:230–41. doi: 10.1002/pca.266510.1002/pca.266528008675]Open DOISearch in Google Scholar
[67. Busch T, Kirschning A. Recent advances in the total synthesis of pharmaceutically relevant diterpenes. Nat Prod Rep 2008;25:318–41. doi: 10.1039/b705652b10.1039/b705652b18389140]Open DOISearch in Google Scholar
[68. Pfeffer TJ, Sasse F, Schmidt CF, Lakämper S, Kirschning A, Scholz T. The natural diterpenetonantzitlolone A its synthetic enantiomer inhibits cell proliferation and kinesin-5 function. Eur J Med Chem 2016;112:164–70. doi: 10.1016/j.ejmech.2016.02.02210.1016/j.ejmech.2016.02.02226896705]Open DOISearch in Google Scholar
[69. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 2011;130:157–76. doi: 10.1016/j.pharmthera.2011.01.01010.1016/j.pharmthera.2011.01.01021277893]Open DOISearch in Google Scholar
[70. Hwang ES, Park KK. Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem 2010;74:961–7. doi: 10.1271/bbb.9078510.1271/bbb.9078520460721]Open DOISearch in Google Scholar
[71. Kang YJ, Park HJ, Chung HJ, Min HY, Park EJ, Lee MA, Shin Y, Lee SK. Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol Pharmacol 2012;82:168–77. doi: 10.1124/mol.112.07853510.1124/mol.112.07853522550094]Open DOISearch in Google Scholar
[72. Li ML, Zhang F, Wang XA, Wu XS, Zhang BT, Zhang N, Wu WG, Wang Z, Weng H, Liu SB, Gao GF, Mu JS, Shu YJ, Bao RF, Cao Y, Lu JH, Gu J, Zhu J, Liu YB. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci 2015;106:1341–50. doi: 10.1111/cas.1276210.1111/cas.12762463801026250568]Open DOISearch in Google Scholar
[73. Shen J, Ma H, Zhang T, Liu H, Yu L, Li G, Li H, Hu M. Magnolol inhibits the growth of non-small cell lung cancer via inhibiting microtubule polymerization. Cell Physiol Biochem 2017;42:1789–801. doi: 10.1159/00047945810.1159/00047945828746938]Open DOISearch in Google Scholar
[74. Wu W-N, Beal JL, Doskotch RW. Alkaloids of thalictrum XXX. Eleven minor alkaloids from Thalictrum rugosum. J Nat Prod 1980;43:143–50. doi: 10.1021/np50007a01410.1021/np50007a014]Open DOISearch in Google Scholar
[75. Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC. Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle 2018;17:652–68. doi: 10.1080/15384101.2017.135651210.1080/15384101.2017.1356512597620628749250]Open DOISearch in Google Scholar
[76. Levrier C, Sadowski MC, Nelson CC, Davis RA. Cytotoxic C20 diterpenoid alkaloids from the Australian endemic rainforest plant Anopterusmacleayanus. J Nat Prod 2015;78:2908–16. doi: 10.1021/acs.jnatprod.5b0050910.1021/acs.jnatprod.5b0050926600001]Open DOISearch in Google Scholar
[77. Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC. 6α-acetoxyanopterine, a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells. Mol Cancer Ther 2017;16:3–15. doi: 10.1158/1535-7163.MCT-16-032510.1158/1535-7163.MCT-16-032527760837]Open DOISearch in Google Scholar
[78. Williams RB, Martin SM, Lawrence JA, Norman VL, O’Neil-Johnson M, Eldridge GR, Starks CM. Isolation and identification of the novel tubulin polymerization inhibitor bifidenone. J Nat Prod 2017;80:616–24. doi: 10.1021/acs.jnatprod.6b0089310.1021/acs.jnatprod.6b0089328335606]Open DOISearch in Google Scholar
[79. Mukhtar E, Mustafa Adhami V, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 2014;13:275–84. doi: 10.1158/1535-7163.MCT-13-07912443544510.1158/1535-7163.MCT-13-0791394604824435445]Search in Google Scholar
[80. Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs 2011;29:984–95. doi: 10.1007/s10637-010-9437-z10.1007/s10637-010-9437-z316055720449627]Open DOISearch in Google Scholar
[81. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents - the epothilones. Biologics 2008;2:789–811. PMCID: PMC272790010.2147/BTT.S3487272790019707459]Search in Google Scholar
[82. Baas PW, Ahmad FJ. Beyond taxol: microtubule-based treatment of disease and injury of the nervous system. Brain 2013;136:2937–51. doi: 10.1093/brain/awt15310.1093//awt153]Open DOISearch in Google Scholar
[83. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004–14. doi: 10.1056/NEJM19950413332150710.1056/NEJM1995041333215077885406]Open DOISearch in Google Scholar
[84. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633–42. doi: 10.1200/JCO.2005.04.054310.1200/JCO.2005.04.054316575015]Open DOISearch in Google Scholar
[85. Ying Z, Xin M, Guanhua D. Microtubule-stabilizing agents: New drug discovery and cancer therapy. Pharmacol Therap 2016;162:134–43. doi: 10.1016/j.pharmthera.2015.12.00610.1016/j.pharmthera.2015.12.00626706241]Open DOISearch in Google Scholar
[86. Tarade D, Pandey S, McNulty J. Review of cytotoxic CA4 analogues that do not target microtubules, implications for CA4 development. Mini Rev Med Chem 2017;17:1507–14. doi: 10.2174/138955751566616050912582910.2174/138955751566616050912582927156516]Open DOISearch in Google Scholar
[87. US National Library of Medicine (NLM). ClinicalTrials.gov [displayed 10 September 2019]. Available at https://clinicaltrials.gov/ct2/results?term=tubulin+inhibitors]Search in Google Scholar
[88. de Lemos E, Porée FH, Bourin A, Barbion J, Agouridas E, Lannou MI, Commerçon A, Betzer JF, Pancrazi A, Ardisson J. Total synthesis of discodermolide, optimization of the effective synthetic route. Chemistry 2008;14:11092–112. doi: 10.1002/chem.2008014781897316210.1002/chem.20080147818973162]Search in Google Scholar
[89. Wender PA, Hegde SG, Hubbard RD, Zhang L. Total synthesis of (-)-laulimalide. J Am Chem Soc 2002;124:4956–7. doi: 10.1021/ja025842810.1021/ja025842811982349]Open DOISearch in Google Scholar
[90. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov 2014;13:588–602. doi: 10.1038/nrd436610.1038/nrd43662503373625033736]Open DOISearch in Google Scholar
[91. Cortes Cabrera A, Lucena-Agell D, Redondo-Horcajo M, Barasoain I, Díaz JF, Fasching B, Petrone PM. Aggregated compound biological signatures facilitate phenotypic drug discovery and target elucidation. ACS Chem Biol 2016;11:3024–34. doi: 10.1021/acschembio.6b0035810.1021/acschembio.6b0035827564241]Open DOISearch in Google Scholar